What is Bronchogen used for in research?

It is studied as a bronchial peptide bioregulator intended to support the function and repair of respiratory tract tissue, and is mainly backed by Russian bioregulator research.

Is Bronchogen a well-validated drug?

No. It is an experimental short peptide with limited published data and no major regulatory approval, so it should be considered a research chemical.

← All peptides

Immune

Research Chemical

Bronchogen

Also known as: Bronchogen

Bronchogen is a short synthetic peptide (Ala-Glu-Asp-Leu) studied as a bronchial bioregulator intended to support respiratory tissue function. It is part of the Russian-developed family of short "Khavinson" peptide bioregulators.

Mechanism of Action

Bronchogen is a tetrapeptide (AEDL) classified as a peptide bioregulator believed to act epigenetically by binding regions of DNA and modulating gene expression in bronchial and pulmonary epithelial cells. It is proposed to normalize expression of genes governing differentiation and function of respiratory tract cells, supporting mucosal repair and reducing local inflammatory signaling. Its tissue-selective activity reflects the bioregulator concept that short peptides restore homeostatic protein synthesis in specific organ systems.

Half-life: Short (minutes), typical of small tetrapeptides cleared rapidly from circulation
Administration Routes: subcutaneous, intramuscular
Research Status: Research Chemical